Principle Wealth Partners LLC Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

Principle Wealth Partners LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 3.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,194 shares of the company’s stock after purchasing an additional 500 shares during the period. Principle Wealth Partners LLC’s holdings in Kenvue were worth $303,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Grove Bank & Trust raised its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue during the 4th quarter worth approximately $29,000. Riverview Trust Co bought a new position in shares of Kenvue during the 3rd quarter worth approximately $30,000. Fortitude Family Office LLC raised its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of Kenvue during the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $20.93 on Wednesday. The company’s fifty day moving average price is $21.46 and its 200 day moving average price is $22.02. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market capitalization of $40.13 billion, a PE ratio of 39.49, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, research analysts predict that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.92%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent analyst reports. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group cut their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.